anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled stable emulsified cosmetic providing a cool and relieved feeling, obtained by blending components comprising a water-soluble high polymer, a specified surface active agent of the polyhydric alcohol fatty ester type, a specific surface active agent, colloidal water-containing silicate, and a liquid oil. CONSTITUTION:The titled emulsified cosmetic obtained by blending at least one water-soluble high polymer selected from pectin, xanthan gum, karaya gum, locust bean gum, carrageenan, dextrin, etc., at least one surface active agent of the polyhydric alcohol fatty ester type (e.g., propylene glycol monostearate, etc.)  having a HLB value of 3.0-7.0, at least one surface active agent (e.g., polyoxyethylene sorbitan monooleate, etc.) having a HLB of 10.0-20.0, a colloidal water-containing silicate (e.g., bentonite, etc.), a liquid oil, pigment, and water. EFFECT:Applicable uniformly, repeatedly, preventing make-up disorder.
Macular edema has been reported in postmarketing experience in diabetic patients who were taking pioglitazone or another thiazolidinedione. Some patients presented with blurred vision or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination. 

Most patients had peripheral edema at the time macular edema was diagnosed. Some patients had improvement in their macular edema after discontinuation of the thiazolidinedione.

Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care. Patients with diabetes who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings [see Adverse Reactions (6.1)].
The invention relates to a novel lipid kinase which is part of the PI3 Kinase family. PI3 Kinases catalyze the addition of phosphate to inositol generating inositol mono, di and triphosphate. Inositol phosphates have been implicated in regulating intracellular signalling cascades resulting in alternations in gene expression which, amongst other effects, can result in cytoskeletal remodelling and modulation of cellular motility. More particularly the invention relates to a novel human PI3 Kinase, p110delta which interacts with p85, has a broad phosphoinositide specificity and is sensitive to the same kinase inhibitors as PI3 Kinase p110alpha. However in contrast to previously identified PI3 Kinases which show a ubiquitous pattern of expression, p110delta is selectively expressed in leucocytes. Importantly, p110delta shows enchanced expression in most melanomas tested and therefore may play a crucial role in regulating the metastatic property exhibited by melanomas. The identification of agents that enhance or reduce p110delta activity may therefore prevent cancer metastasis.
A device ( 10 ) for preventing leakage of gas from a lens capsule of an eye, to which a capsulorhexis has been made, during manipulations performed inside the lens capsule. It includes a tube ( 12 ) having at least one lumen ( 14 ). The tube is provided with at least one barrier member ( 16; 17 ) such that gas that has been introduced into the lens capsule is prevented to escape therefrom. It also relates to a method of eye surgery. It includes making an incision to gain access to the interior of an eye. Making a capsulorhexis in the lens capsule. Removing the lens from the lens capsule of an eye. Sealing the capsulorhexis with a sealing device, to provide gas leakage proof sealing. Expanding the lens capsule with a gas. Performing a desired operation inside the expanded lens capsule.
The invention provides a nanoencapsulated natural polyphenol composition. These encapsulated polyphenols enable its formulation as a dietary supplement for nutraceuticals, functional foods and/or enriched foods with neuro-protective functionality. In an embodiment of the invention, the polyphenols correspond to tannins derived from grapes. In a preferred embodiment of the invention, the polyphenols or tannins are encapsulated in liposomes. The invention also relates to the method for obtaining the composition. In addition to benefitting health and increasing its bioavailability, the encapsulated polyphenols or tannins allow the stability of foods to be improved, maintaining their physical properties and antioxidants.
Space flights have shown the possibilities and limitations of human adaptation to space. For the last 50 years, results showed that the space environment and microgravity in particular, cause changes that may affect the performance of astronauts. These physiological changes particularly challenge the cardiovascular, metabolic, muscle and bone functions. Space agencies regularly conduct simulations on the ground on healthy volunteers to mimic the effects of weightlessness (head down bed rest model) to better understand the mechanisms of adaptations of the organism to space, and develop ways to prevent and / or reduce the negative biological effects of microgravity on astronauts. These protocols are called countermeasures. Since the beginning of space missions, various countermeasures have been tested on the ground and in-flight, including different exercise protocols. To date, however, none has been entirely satisfactory and space agencies continue to conduct simulation studies to evaluate new countermeasures. Nowadays, the human spaceflight program has entered the next phase of space exploration towards the Moon and Mars and there are clearly inherent medical challenges with such a goal, among which, countermeasure developments are a clear priority.

Based on recent evidences, the next countermeasure to be tested during a 60-day bed rest includes a nutritional countermeasure composed of an anti-oxidant and anti-inflammatory dietary mix.
In the ATLAS study participants were asked, after they had transitioned back to conventional oral antiretroviral therapy, whether they preferred injectable or oral treatment. Their feedback on their preference overwhelming favoured injectables9. Women and men will be recruited from existing Ezintsha programs operating within the pharmacies, using current government criteria for Pre-exposure Prophylaxis initiation. Pre-exposure Prophylaxis will be initiated and monitored according to these and the Pharmacist-Initiated Management of Antiretroviral Therapy guidelines. Pre-exposure Prophylaxis, through these programs, will be offered free of charge. The study is designed to be as "real-world" as possible. Adaptations to routine Pre-exposure Prophylaxis guidelines have been made to accommodate visit-based HIV testing (based on the injectable regimens, which require more frequent access to the clinic). Participant reimbursement will therefore be for the baseline, mid and end-of-study interviews in participants consenting to these interviews. The maximum amount of time a participant in the study can be on either Cabotegravir Long-Acting Injectable or oral Pre-exposure Prophylaxis, or a combination, or, indeed, on neither drug, is therefore 15 months (and an additional three months on oral Pre-exposure Prophylaxis during the transition, as standard of care).

The Investigator anticipates that participants will favour Cabotegravir Long-Acting Injectable, but also anticipates that there may be interesting patterns of use when they learn that they may defer access to Cabotegravir Long-Acting Injectable or oral Pre-exposure Prophylaxis. Participants may favour Pre-exposure Prophylaxis, as they may prefer three monthly visits over the two monthly injection requirements. The Investigator may see participants initially choosing oral Pre-exposure Prophylaxis, and then moving to Cabotegravir Long-Acting Injectable, or even vice versa. The Investigator is unclear on what men may favour versus women. The Investigator will endeavor to recruit at least 20 men in the study, appreciating that not much is known about this group in the sub-Saharan Africa context. One of the most important analyses that will flow from information collected when assessing for Pre-exposure Prophylaxis eligibility is the risk profile of the participants taking up Pre-exposure Prophylaxis, a key issue when assessing cost-effectiveness. Finally, the investigator is not excluding women or men who defer Pre-exposure Prophylaxis initially. These various combinations will provide interesting quantitative, but more importantly, qualitative data on preferences, and on how services may be improved to accommodate participants' choices.
This single site study will be conducted at the UT Southwestern Simmons Cancer Center. This study is designed to measure drug concentrations in the blood of 18 female breast cancer patients who require doxorubicin (30 minute infusion) and cylcophosphamide (30 minute infusion) as part of standard medical care. Up to a total of 40 adult female participants will be consented for the study at the cancer center. Eighteen of these participants are needed to complete the study. The others will likely be screen failures. The participants will have no more than 100 ml of blood drawn via a peripheral intravenous catheter just prior to the doxorubicin infusion, and then at 0.5, 1, 1.5, 2, 3, 4, 5, 12-24, and 24-72 h after the beginning of the doxorubicin infusion. The 5 hour blood draw is optional. The intravenous catheter will be removed when the participant is discharged from the cancer center on day 1. The participant will be asked to return to the cancer center at 12-24 and 24-72 hours to have the final 2 blood draws conducted.

The participants must be treated with Doxurubicin and Cyclophosphamide in order to participate in this pharmacokinetic analysis study.
PURPOSE: To obtain a medicinal preparation which is obtained by coating aspirin granules with a composition consisting of a specific ethyl acrylate-methyl methacrylate copolymer, hydroxypropylmethylcellulose(HPMC), sodium chloride and talc and releases aspirin in the zero-order rate at the prescribed time and the low dose. CONSTITUTION: This preparation is obtained by coating aspirin granules with a composition consisting of (A) 40-60 pts.wt. of a copolymer which possesses an average molecular weight of 800,000 and contains ethyl acrylate and methyl methacrylate in a proportion of 70:30, (B) 10-20 pts.wt. of hydroxypropylmethylcellulose(HPMC) which shows ASTM viscosity of 3-15 cps and contains hydroxypropyl and methoxyl in amounts of 7-12wt.% and 28-30wt.%. respectively, (C) 1-12 pts.wt. of sodium chloride, (D) 20-45 pts.wt. of talc USP and (E) 200-900 pts.wt. of water. This preparation releases aspirin by zero-order reaction with elution velocity of 5-15mg/hr during 5-8 hours. The preparation suppresses the production of thromboxane B2 due to platelet without suppressing the production of prostacyclin and is useful for prevention and treatment of vascular obstructive diseases.
The study consists of three work packages. Wave 1 participants will be included in all work packages.
Participants in the intervention arm will receive the Hoosier Sport intervention 2-3 times a week (twice in PE class, and once in home room). This will involve learning new sport, exercise, and nutrition knowledge, as well as developing leadership skills.
Acute post-injection back pain reactions have been reported in the postmarketing period in patients treated with XIAFLEX for Peyronie’s disease [see Adverse Reactions (6.4)]. These events typically have an onset immediately or within minutes of injection. The acute lower back pain can be mild to severe in intensity and can radiate to the legs, arms and chest. Other systemic symptoms, such as chest pain, headache, and dyspnea, have been reported along with back pain episodes. None of the events were reported to occur after the patient’s first XIAFLEX injection and a few were reported to occur during a second treatment course [see Dosage and Administration (2.2)]. Reported events typically resolved within 15 minutes, but some lasted up to 30 minutes, and one event lasted 1.5 hours. Reported events typically did not require intervention, but some required observation and treatment with analgesics.
The invention relates to a composition capable of removing pockmarks and inhibiting acne generation, and application thereof. The composition comprises a component A and a component B. The component A comprises the following raw materials by weight: 0.1 to 1 part of phytosterol, 0.1 to 2 parts of bisabolol and 0.1 to 1 part of octadecanol glycyrrhetinate. The component B comprises the following raw materials by weight: 0.1 to 1 part of phloretin, 0.5 to 5 parts of acetyl chitosamine, 0.05 to 1 part of heparin sodium, 0.1 to 1 part of asiaticoside and 0.1 to 2 parts of troxerutin. A ratio of the component A to the component B is 0.3-3: 0.85-10. The invention has the following characteristics: all the raw materials are included in the List of Approved Raw Materials for Cosmetics of China; the problems of great usage amount, slow action and generation of new acne in a pockmark removal period of pockmark-removing products prepared from crude plant extract are overcome; and the pockmark-removing composition prepared in the invention is capable of eliminating red acne marks, fading black acne marks, restoring acne scars and inhibiting generation of new acne.
Disclosed a pharmaceutical composition including one of crotoxin, mojavetoxin or a related toxin and a carrier for use in the treatment of chronic pain, especially to the treatment of heretofore intractable pain such as that associated with advanced cancer wherein the treatment is independent of the reduction of tumors. The crotoxin is preferably obtained from the snake  Crotalus durissus terrificus  and the mojavetoxin is obtained from the rattlesnake  Crotalus scutulatus scutulatus . Preferably the composition further comprises an effective amount of acetylsalicylic acid whereby the toxin and acetylsalicylic acid together produce a synergistic effect providing enhanced pain relief. The composition of the invention may be delivered in parenteral (i.p.) (intravenous, intramuscular or subcutaneous) applications. Alternatively, the composition may be applied as a topical application. The biological activity of the composition is characterized by its ability to bind to presynaptic and postsynapic receptor sites. This results in an inhibition of aceylcholine release and activity.
Among critical congenital heart lesions, hypoplastic left heart syndrome (HLHS) and related single right ventricle (RV) anomalies are associated with the highest morbidity and mortality. The first stage in palliation for patients with these defects is the Norwood procedure. The essential components of the Norwood procedure include (1) an atrial septectomy, (2) anastomosis of the proximal pulmonary artery to the aorta with homograft augmentation of the aortic arch, and (3) establishment of a source of pulmonary blood flow, with either a modified Blalock-Taussig shunt (MBTS) or the right ventricle to pulmonary artery (RV-to-PA) shunt. In May 2005, the Pediatric Heart Network began a multi-center, randomized trial, the Single Ventricle Reconstruction (SVR) Trial, comparing outcomes in subjects with HLHS or other single RV anomalies palliated using the Norwood procedure with either a MBTS or the RV-to-PA shunt. The primary outcome of this trial was freedom from death or cardiac transplantation by 12 months post-randomization.

The Single Ventricle Reconstruction Extension (SVR II) Study is an extension of the SVR Trial that compares clinical outcomes and RV performance following the RV-to-PA shunt versus MBTS modifications of the Norwood procedure in subjects at 6 years post-randomization. Data is collected annually between ages 2 and 6 years, as well as before and after the Fontan surgery. Vital status and medical history is ascertained annually until the last enrolled subject is 6 years old. Data is obtained through medical record review, phone interview with the parent or guardian, electrocardiography (ECG), core laboratory analysis of echocardiographic images and Holter monitors, and completion of questionnaires regarding neurodevelopmental outcomes, behavior, health-related quality of life, and family functioning. The primary outcome variable in SVR II will be freedom from death or cardiac transplantation at 6 years post-randomization. All subjects who were randomized in the SVR trial will be included in analysis of this endpoint.
OBJECTIVES: To assess the diagnostic performance of ultrasonography in pre-operative assessment of lymph nodes in patients with cervical cancer, to compare the outcomes for pelvic and para-aortic regions, and to detect macrometastases and micrometastases separately.
METHODS: Patients were retrospectively included if they met the following inclusion criteria: pathologically verified cervical cancer; ultrasonography performed by one of four experienced sonographers; surgical lymph node staging, at least in the pelvic region-sentinel lymph node biopsy or systematic pelvic lymphadenectomy or debulking. The final pathological examination was the reference standard.
RESULTS: 390 patients met the inclusion criteria between 2009 and 2019. Pelvic node macrometastases (≥2 mm) were confirmed in 54 patients (13.8%), and micrometastases (≥0.2 mm and <2 mm) in another 21 patients (5.4%). Ultrasonography had sensitivity 72.2%, specificity 94.0%, and area under the curve (AUC) 0.831 to detect pelvic macrometastases, while sensitivity 53.3%, specificity 94.0%, and AUC 0.737 to detect both pelvic macrometastases and micrometastases (pN1). Ultrasonography failed to detect pelvic micrometastases, with sensitivity 19.2%, specificity 85.2%, and AUC 0.522. There was no significant impact of body mass index on diagnostic accuracy. Metastases in para-aortic nodes (macrometastases only) were confirmed in 16 of 71 patients who underwent para-aortic lymphadenectomy. Ultrasonography yielded sensitivity 56.3%, specificity 98.2%, and AUC 0.772 to identify para-aortic node macrometastases.
CONCLUSION: Ultrasonography performed by an experienced sonographer can be considered a sufficient diagnostic tool for pre-operative assessment of lymph nodes in patients with cervical cancer, showing similar diagnostic accuracy in detection of pelvic macrometastases as reported for other imaging methods (18F-fluorodeoxyglucose positron emission tomography/CT or diffusion-weighted imaging/MRI). It had low sensitivity for detection of small-volume macrometastases (largest diameter <5 mm) and micrometastases. The accuracy of para-aortic assessment was comparable to that for pelvic lymph nodes, and assessment of the para-aortic region should be an inseparable part of the examination protocol.
The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text "WARNING: High in added sugar" (task 2).
Described is a system for generating simulated CT images. The system can include a CT image simulator, a phantom database, and a scanner database. The phantom database can include one or more virtual phantoms while the scanner database can include information about one or more CT scanners, including a subject CT scanner. The CT image simulator can use information about a subject patient, a virtual phantom, and scanner information about the subject CT scanner to generate a simulated CT image that closely simulates what an actual CT image would look like if performed on the subject patient using the subject CT scanner. The simulated CT image can be displayed on a display screen. Also described is a method of generating a simulated CT image and CT image simulator software that can be used to generate a simulated CT image.
As the final manifestation of cardiovascular disease and the main cause of death, heart failure is one of the important challenges threatening human health in the 21st century. In 2016, the European Heart Association proposed a new classification standard for heart failure. In particular, for the first time, heart failure with median ejection fraction has been clearly defined. These patients have received more and more attention, but there are still relatively few studies on them. More research is needed to improve our understanding of this part of the population in order to make the best clinical decisions and improve the prognosis. 3D speckle tracking technology is a new technology developed on the basis of real-time three-dimensional echocardiography and speckle tracking technology. It is gradually recognized in the evaluation of left ventricular systolic and diastolic function, especially in the evaluation of cardiotoxicity of chemotherapy drugs. At present, the application of 3D-STI in the evaluation of left ventricular systolic function in heart failure with median ejection fraction is limited and needs further study.In this study, 3D-STI was used to evaluate left ventricular systolic function in heart failure with median ejection fraction.
Infants received two primary vaccinations with Pneumosil, the first at age 6 weeks and the second at age 14 weeks. A booster vaccination was given between 9 and 16 months of age.
In three cystometric studies performed in patients with involuntary detrusor contractions, increased bladder capacity was demonstrated by an increased volume threshold for unstable contractions and diminished frequency of unstable detrusor contractions after darifenacin extended-release tablet treatment. These findings are consistent with an antimuscarinic action on the urinary bladder.

Electrophysiology

The effect of a six-day treatment of 15 mg and 75 mg darifenacin on QT/QTc interval was evaluated in a multiple-dose, double-blind, randomized, placebo- and active-controlled (moxifloxacin 400 mg) parallel-arm design study in 179 healthy adults (44% male, 56% female) aged 18 to 65. Subjects included 18% poor metabolizer (PMs) and 82% extensive metabolizer (EMs). The QT interval was measured over a 24-hour period both predosing and at steady-state. The 75 mg darifenacin extended-release tablets dose was chosen because this achieves exposure similar to that observed in CYP2D6 poor metabolizers administered the highest recommended dose (15 mg) of darifenacin in the presence of a potent CYP3A4 inhibitor. At the doses studied, darifenacin did not result in QT/QTc interval prolongation at any time during the steady-state, while moxifloxacin treatment resulted in a mean increase from baseline QTcF of about 7.0 msec when compared to placebo. In this study, darifenacin 15 mg and 75 mg doses demonstrated a mean heart rate change of 3.1 and 1.3 bpm, respectively, when compared to placebo. However, in the clinical efficacy and safety studies, the change in median HR following treatment with darifenacin was no different from placebo.
Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined. There is also described a kit for use in such a method, as well as an immunoregulatory drug capable of blocking down-modulation of a ligand-induced receptor.